Navigation Links
Cancer risk found for long-term hormone therapy

Using postmenopausal hormone therapy for more than 15 years increases a woman's risk of developing breast cancer, particularly among leaner women according to research at the Keck School of Medicine of the University of Southern California (USC).

An analysis of the California Teachers Study focused on postmenopausal hormone therapy use among more than 55,000 women for nearly 10 years. The research was conducted by a team including first author Tanmai Saxena, an M.D. Ph.D student at the Keck School. The research was published today in Cancer Epidemiology, Biomarkers and Prevention, an American Association for Cancer Research journal.

Compared with women who never used postmenopausal hormone therapy, women who used estrogen therapy for more than 15 years were at a 19 percent increased risk of breast cancer. The risk was even more pronounced for women who used combined therapy with estrogen plus progestin for 15 or more years. These women had an increased risk of 83 percent, Saxena said.

"This study shows that there needs to be a personalized conversation with women about the risks of using postmenopausal hormone therapy," said Saxena. "Different women appear to have different risks from hormones."

Thinner women who go on hormone therapy also appear to be at higher risk, Saxena said.

The research revealed that body mass index (BMI) may be an indicator of breast cancer risk for women who use postmenopausal hormone therapy. Women with a BMI of 30 or less appear to be at increased risk of breast cancer from combined therapy, while women with a BMI of 30 or higher were at less risk. Women with a BMI of 25 or less were at the highest risk.

The purpose of the study was to elaborate on the Women's Health Initiative findings regarding the effects of postmenopausal hormone therapy on breast cancer risk. The 15-year WHI, conducted by the National Institutes of Health, was halted in 2002 after increased risks of cardiovascular disease and breast cancer were found among women who were taking combination therapy as part of the trial. This study looked at the risk associated with particular formulations of combination hormone therapy as well as the subtypes of breast cancer resulting.


Contact: Leslie Ridgeway
University of Southern California

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, the ... pharmaceutical innovations, today announced it has signed ... Fund (KDDF) to foster collaboration between KDDF and HUYA ... commercialization of healthcare products for the global market. ... important source of new innovative preclinical and clinical stage ...
(Date:11/30/2015)... Florida and MAGDEBURG, Germany , ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... --> NovaVision, a wholly owned subsidiary of Vycor ... European version of its Internet-delivered NovaVision Therapy Suite at the ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 BrainStorm ... developer of adult stem cell technologies for neurodegenerative diseases, today ... been awarded an additional grant of approximately $735,000 from ... This grant, the second this year, brings the total awarded ... million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
Breaking Biology Technology: